Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tenaya Therapeutics Inc

0.4400
-0.5069-53.53%
Post-market: 0.4303-0.0097-2.20%19:59 EST
Volume:26.27M
Turnover:12.91M
Market Cap:34.86M
PE:-0.31
High:0.7000
Open:0.7000
Low:0.3941
Close:0.9469
Loading ...

Company Profile

Company Name:
Tenaya Therapeutics Inc
Exchange:
NASDAQ
Establishment Date:
2016
Employees:
140
Office Location:
171 Oyster Point Boulevard,Suite 500,South San Francisco,California,United States
Zip Code:
94080
Fax:
- -
Introduction:
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Directors

Name
Position
Faraz Ali
Chief Executive Officer, Secretary and Director
Catherine Stehman Breen
Director
David V. Goeddel
Director
Deepak Srivastava
Director
Eli Casdin
Director
JeenJoo Kang
Director
Jeffrey T. Walsh
Director
Jin Long Chen
Director
R. Sanders Williams
Director

Shareholders

Name
Position
Faraz Ali
Chief Executive Officer, Secretary and Director
Leone D. Patterson
Chief Financial and Business Officer
Timothy Hoey
Chief Scientific Officer
Whittemore Tingley
Chief Medical Officer